from the quickly evolving subject of oncology study, exact and economical mutation screening is vital for building targeted therapies. The KRAS solutions Platform plays a pivotal part With this landscape by presenting detailed solutions for KRAS mutation profiling and Investigation. KRAS mutations, present in about ninety five% of RAS-linked oncoge